Threshold Pharmaceuticals Inc. (Nasdaq: THLD) reported disappointing results from two Phase 3 studies of its cancer treatment evofosfamide sending the stock price plummeting $2.72 to $0.62.
Disappointing study results for Threshold Pharmaceuticals
December 07, 2015 at 13:10 PM EST
